Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.79
-0.2100-0.15%
Post-market: 144.040.2500+0.17%18:37 EDT
Volume:8.29M
Turnover:1.19B
Market Cap:354.75B
PE:112.97
High:144.15
Open:143.85
Low:142.32
Close:144.00
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.96
T/O Rate:0.34%
Dividend:3.36
Dividend Rate:2.34%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.46
PE(LYR):19.75

Loading ...

Merck’s Lipfendra® (enlicitide) is the First and Only Once-daily Oral Pcsk9 Inhibitor Approved by the U.S. FDA to Reduce Ldl-c in Adults with Hypercholesterolemia

THOMSON REUTERS
·
Jul 16

Merck: FDA Approves Lipfendra Tablets 20 Mg to Reduce Low-density Lipoprotein Cholesterol in Adults with Hypercholesterolemia

THOMSON REUTERS
·
Jul 16

Citi Sticks to Its Hold Rating for Merck & Company (MRK)

TIPRANKS
·
Jul 16

Merck Buy Rating Reiterated as sac-TMT Data De-Risk Oncology Pipeline; 12-Month Price Target Maintained at $137

TIPRANKS
·
Jul 16

Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled

TradingKey
·
Jul 15

Movement Alert|Merck Rises 3.06% in Regular Trading, Keytruda Phase 3 Endometrial Cancer Trial Meets Primary Endpoint

Market Focus
·
Jul 15

Merck Shares Rise 3% After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

THOMSON REUTERS
·
Jul 15

Sector Update: Healthcare Stocks Decline Premarket Wednesday

MT Newswires Live
·
Jul 15

Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions

MT Newswires Live
·
Jul 15

Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial

Market Focus
·
Jul 15

Merck to Unveil New HIV Pipeline Data at AIDS 2026, Featuring Daily, Weekly, and Monthly Regimens

Deep News
·
Jul 15

Merck Rises After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

Reuters
·
Jul 15

Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial

Reuters
·
Jul 15

Merck to present new data from research pipeline for HIV treatment, prevention

TIPRANKS
·
Jul 15

Merck Hosts Virtual HIV Investor Event Aug. 3 After AIDS 2026 Data Presentations

Reuters
·
Jul 15

Merck says Phase 3 KEYNOTE-C93 trial of Keytruda met primary endpoint

TIPRANKS
·
Jul 15

Merck Says Keytruda Monotherapy Improves PFS in Phase 3 Trial for Dmmr Endometrial Cancer

Reuters
·
Jul 15

Keytruda® (pembrolizumab) as Monotherapy Significantly Improved Progression-free Survival (pfs) in Certain Patients with Advanced or Recurrent Endometrial Cancer with Mismatch Repair Deficient (dmmr) Tumors Compared to Chemotherapy

THOMSON REUTERS
·
Jul 15

Merck & Co - Phase 3 Keynote-c93 Trial Meets Primary Endpoint of Progression-free Survival

THOMSON REUTERS
·
Jul 15

Merck & Co - Interim Analysis Shows Trend Toward Improved Os for Keytruda; Os Data not Mature

THOMSON REUTERS
·
Jul 15